CORONA Remedies Q4 FY26 Results: Board Approves Unmodified Financials & ₹10 Dividend
CORONA Remedies Limited announced its audited standalone and consolidated financial results for Q4 FY26. The company recommended a final dividend of ₹10 per share. Key auditor appointments and re-appointments were approved, including Statutory Auditors for five years. Dr. Kirtikumar Mehta's re-appointment as Chairman was also recommended.
The announcement includes the approval of financial results and a dividend recommendation, which are material for investors. The appointment of auditors and directors, while routine, also impacts corporate governance. The overall financial performance, though not detailed in the summary, is a key factor.
The company reported its financial results with unmodified audit reports and recommended a dividend, which are positive indicators for shareholders. The approval of financial results and auditor appointments contribute to a positive sentiment.
CORONA Remedies Limited announced the outcome of its Board Meeting held on May 11, 2026. The Board, on the recommendation of the Audit Committee, approved the Audited Standalone and Consolidated Financial Results for the fourth quarter and the year ended March 31, 2026. The company also declared that the Auditor's reports on these financial results are unmodified.
Furthermore, the Board recommended a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26, subject to shareholder approval at the ensuing Annual General Meeting (AGM). The company has fixed Friday, June 19, 2026, as the record date for this dividend. The dividend, if declared, will be paid on or before August 07, 2026.
Key appointments and re-appointments were also approved. M/s. Walker Chandiok & Co LLP have been recommended as Statutory Auditors for five years (FY 2026-27 to FY 2030-31), subject to member approval. M/s. Dhara Patel has been recommended as Secretarial Auditor for five years (from FY 2026-27), and M/s. Shah & Shah Associates as Internal Auditors for FY 2026-27. M/s. Manish B. Analkat has been recommended for re-appointment as Cost Auditor for FY 2026-27.
Additionally, the Board recommended the re-appointment of Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for a term of five years from April 01, 2027, subject to shareholder approval. The Board meeting commenced at 2:30 p.m. and concluded at 4:00 p.m.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.